Navigation Links
Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz
Date:8/23/2014

Albany, NewYork (PRWEB) August 23, 2014

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Full Report With TOC @ http://www.researchmoz.us/critical-care-therapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market-report.html

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
  • Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
  • Key drivers and restraints that have had and are expected to have a significant impact on the market
  • An overview of major licensing and co-development agreements that could affect growth trends

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

Reasons to Buy

  • The report will enhance your decision-making capability by allowing you to:
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

For More Information Kindly Contact:
Email: sales(at)researchmoz(dot)us   
Blog: http://industryresearchnews.blogspot.com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12114682.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Primary care physicians can be critical resource for abused women in rural areas
2. CHEST releases new expert guidance in care of the critically ill and injured
3. Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting
4. Proteins critical to wound healing identified
5. United Nations Foundation Mobilizes Critical Support for the Millennium Development Goals
6. Central Ohio Trauma System (COTS) Relies on Onset Technology's OnPage® Critical Messaging Alerts System When Disaster Strikes
7. European Super Critical Fluid Chromatography Reagents Market is Expected to Reach $75.5 million in 2018 - New Report by MicroMarket Monitor
8. North America Super Critical Fluid Chromatography (Reagents) Market is Expected to Reach $107.8 Million in 2018 - New Report by MicroMarket Monitor
9. How critically ill infants can benefit most from human milk
10. Pyruvate oxidation is critical determinant of pancreatic islet number and β-cell mass
11. The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Axiad IDS , a leading provider of trusted identities ... the company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this ... and proactively address potential cybersecurity threats before they happen. The annual list ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... a 2017 Best in KLAS category winner, has named Daniel P. Bullington as ... and enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and ... in Las Vegas, NV, and the importance of treating it immediately. They ... leading care for peri-implantitis, with or without a referral. As experienced periodontists and ...
(Date:5/23/2017)... ... ... New patients with symptoms of gum disease in San Diego, ... treatments from the doctors at Art of Dentistry, without first receiving a referral. Drs. ... of receiving qualified treatment in order to avoid systemic health effects associated with untreated ...
(Date:5/22/2017)... Mt. Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced ... can be administered for a variety of treatments. One or more sedation methods may ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
(Date:5/6/2017)... 5, 2017  May is Stroke Awareness Month and ... most important methods to prevent a stroke: monitor and ... Disease Control and Prevention, undetected and uncontrolled hypertension is ... the global leader in personal heart health technology, recently ... heart attack and stroke and is advancing a national ...
(Date:5/4/2017)...  Fortuna Fix Inc. (" Fortuna "), a private, ... eliminate the need for embryonic and fetal stem cells by ... Fortuna announced today the launch of ... , MD, PhD; Father Kevin FitzGerald , S.J., PhD; ... James Giordano , PhD. "We are excited ...
Breaking Medicine Technology: